HMG-CoA reductase inhibitors
著者
書誌事項
HMG-CoA reductase inhibitors
（Milestones in drug therapy）
Birkhäuser, c2002
大学図書館所蔵 件 / 全4件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographies and index
内容説明・目次
内容説明
HMG-CoA reductase inhibitors (statins) are established drugs for the
treatment of hypercholesterolemia. Furthermore, they induce regression
of vascular atherosclerosis as well as reduction of
cardiovascular-related morbidity and death in patients with and without
coronary artery disease. This book deals with statins which have
substantially altered the approach to therapy of atherosclerosis and its
sequelae. Emphasis is placed on the scientific background to the
discoveries and the development of the therapy, including an overview of
the current state of knowledge of the drugs. Clinical data are reviewed
extensively. This book not only provides the reader with valuable
information but also stimulates further research into the pathogenesis
of atherosclerosis and the mechanisms behind the action of effective
statins. It sets the stage for creative thinking among scientists of
many disciplines for the accomplishment of our ultimate goals in
treating atherosclerosis and its sequelae. This topical volume...
目次
List of contributors. Preface. Stefano Bellosta, Rodolpho Paoletti, Alberto Corsini: History and development of HMG-CoA reductase inhibitors. Margaret E. Brousseau and Ernst J. Schafer: Structure and mechanisms of action of HMG-CoA reductase inhibitors. Joerg Kotzka, Wilhelm Krone and Dirk Muller-Wieland: Sterol-regulatory element binding proteins (SREBPs): gene regulatory target of statin action. Gerd Schmitz and Michael Torzewski: Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). Koichi Node and James K. Liao: Effects of HMG-CoA reductase inhibitors on cells of the vascular wall - pleiotropic effects of HMG-CoA reductase inhibitors. Hans-Peter Thomas and Elisabeth Steinhagen-Thiessen: Indications and contraindications for statin treatment (primary and secondary prevention of hypercholesterolemia). Helena K. Gylling and Tatu A. Miettinen: Clinical experience: studies with HMG-CoA reductase inhibitors. C. Berry, A. Davie and J. McMurray: Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease. Index
「Nielsen BookData」 より
